Vertaling van "new technologies " (Nederlands → Frans) :

TERMINOLOGIE

epizootisch hemorrhagische ziekte, New Jersey-virus
virus Epizootic hemorrhagic disease, New Jersey

New Minto-virus
virus New Minto

IN-CONTEXT TRANSLATIONS

‘How can new Media and new Technologies improve the dissemination of OSH knowledge and how to measure relevance and impact?’ FR Paris, 18-09-2013
‘How can new Media and new Technologies improve the dissemination of OSH knowledge and how to measure relevance and impact?’ FR Paris, 18/09/2013

in het Engels: Summary - Green jobs and occupational safety and health: Foresight on new and emerging risks associated with new technologies by 2020 (PDF)
Résumé du rapport: Résumé - Prospective sur les risques nouveaux et émergents liés aux nouvelles technologies d’ici à 2020 (PDF)

Lees het volledige rapport in het Engels: Green jobs and occupational safety and health: Foresight on new and emerging risks associated with new technologies by 2020 (PDF)
Lire le rapport complet en anglais: Green jobs and occupational safety and health: Foresight on new and emerging risks associated with new technologies by 2020 (PDF)

- Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies.
- Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, et al. Pathogen inactivation: making decisions about new technologies.

Designer and manufacturer of new technology voor behandelingen in cosmetische dermatologie
Concepteur, fabricant de nouvelles technologies pour traitements dermatologiques cosmétiques

66. Irwig L, Houssami N, van Vliet C. New technologies in screening for breast cancer: a systematic review of their accuracy.
65. Flobbe K, Nelemans PJ, Kessels AGH, Beets GL, von Meyenfeldt MF, van Engelshoven JMA. The role of ultrasonography as an adjunct to mammography in the detection of breast cancer. a systematic review.

European Group on Ethics in Science and New Technologies; [http ...]
European Group on Ethics in Science and New Technologies; [http ...]

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Naar aanleiding van een parlementaire vraag (nr. K533 op 22/08/05) en diverse vragen vanuit ziekenhuizen aan de administratie en onderzoeksinstellingen zoals het VITO (Vlaamse Instelling voor Technologisch Onderzoek), brengt de nieuwe werkgroep “New Communication Technologies”, die nu de niet-ioniserende straling behandelt, dan ook, op eigen initiatief, aanbevelingen uit omtrent het gebruik van draadloze communicatiesystemen en GSM in ziekenhuizen.
Suite à une question parlementaire (n°K533 du 22/08/05) et aux diverses questions émanant des hôpitaux à l’attention de l’administration et des organismes de recherche tels que le VITO (Vlaamse Instelling voor Technologisch Onderzoek), le nouveau groupe de travail « New Communication Technologies », qui s’occupe actuellement des radiations non ionisantes, émet dès lors de sa propre initiative, des recommandations au sujet de l’utilisation des systèmes de communication sans fil et des GSM dans les hôpitaux.

We assess the potential effects of our operations on the environment – and the health and safety of our associates and neighbors – to ensure that the benefits of new products, processes and technologies outweigh any risks.
Nous évaluons toujours les effets possibles de nos activités sur l’environnement – de même que sur la santé et la sécurité de nos collaboratrices et collaborateurs et de ceux qui nous entourent – afin de nous assurer que les bénéfices de nouveaux produits, de nouveaux procédés ou de nouvelles technologies sont supérieurs aux risques potentiels.